The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 09, 2021

Filed:

Oct. 28, 2019
Applicants:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Eureka Therapeutics, Inc., Emeryville, CA (US);

Inventors:

Nai-Kong V. Cheung, New York, NY (US);

Mahiuddin Ahmed, Verona, NJ (US);

Andres Lopez-Albaitero, New York, NY (US);

Cheng Liu, Emeryville, CA (US);

Su Yan, State College, PA (US);

Jingyi Xiang, Walnut Creek, CA (US);

Hong Liu, El Sobrante, CA (US);

Assignees:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Eureka Therapeutics, Inc., Emeryville, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/08 (2006.01); C07K 16/46 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); C07K 16/085 (2013.01); C07K 16/2809 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.


Find Patent Forward Citations

Loading…